Lomitapide: a review of its clinical use, efficacy, and tolerability

References

• Goldstein JK, Hobbs HH, Brown MS. Familial Hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:2863–2913.
   Google Scholar
• Cuchel M, Bruckert E, Ginsberg H, et al. Homozygous familial Hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on familial Hypercholesterolemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146–2157. doi:10.1093/eurheartj/ehu274
   PubMed Web of Science ®Google Scholar
• Benn M, Watts G, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956–3964. doi:10.1210/jc.2012-1563
   PubMed Web of Science ®Google Scholar
• Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36:560–565. doi:10.1093/eurheartj/ehu058
   PubMed Web of Science ®Google Scholar
• Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J. 1980;281:633–636. doi:10.1136/bmj.281.6241.633
   PubMed Web of Science ®Google Scholar
• Raal F, Santos R. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–268. doi:10.1016/j.atherosclerosis.2012.02.019
   PubMed Web of Science ®Google Scholar
• Alonso R, Díaz-Díaz JL, Arrieta F, et al. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry. J Clin Lipidol. 2016;10:953–961. doi:10.1016/j.jacl.2016.04.006
   PubMed Web of Science ®Google Scholar
• Raal F, Sjouke B, Hovingh GK, Isaac BF. Phenotype diversity among patients with homozygous familial Hyercholesterolemia: a cohort study. Atherosclerosis. 2016;248:238–244. doi:10.1016/j.atherosclerosis.2016.03.009
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, Du Toit Theron H, et al; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–46. doi:10.1016/S0140-6736(12)61731-0
   PubMed Web of Science ®Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 385;2015:341–350. doi:10.1016/S0140-6736(14)61374-X
   PubMed Web of Science ®Google Scholar
• Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203858Orig1s000ltr_replace.pdf.
   Google Scholar
• European Medicines Agency. Lojuxta (lomitapide). 2013. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta.
   Google Scholar
• Gordon DA. Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly. Curr Opin Lipidol. 1997;8:131–137.
   PubMed Web of Science ®Google Scholar
• Welty F. Hypobetalipoproteinemia and Abetalipoproteinemia. Curr Opin Lipidol. 2014;25:161–168. doi:10.1097/MOL.0000000000000072
   PubMed Web of Science ®Google Scholar
• Lin M, Zhao S, Shen L, Xu D. Potential approaches to ameliorate heptic fat accumulation seen with MTP inhibition. Drug Saf. 2014;37:213–224. doi:10.1007/s40264-014-0147-x
   PubMed Web of Science ®Google Scholar
• Khoury E, Brisson D, Roy N, Tremblay G, Gaudet D. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Expert Opin Drug Saf. 2019. doi:10.1080/14740338.2019.1602606
   PubMed Web of Science ®Google Scholar
• Perry C. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013;13:285–296. doi:10.1007/s40256-013-0030-7
   PubMed Web of Science ®Google Scholar
• Tuteja S, Duffy D, Dunbar RL, et al. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy. 2014;34:222–239.
   Web of Science ®Google Scholar
• Cuchel M, Bloedon LT, Szapary P, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–156. doi:10.1056/NEJMoa061189
   PubMed Web of Science ®Google Scholar
• Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497–505. doi:10.1038/ncpcardio1250
   PubMedGoogle Scholar
• Harada-Shiba M, Ikewaki K, Nohara A, et al. Efficacy and safety of Lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2017;24:402–411. doi:10.5551/jat.38216
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Blom D, Averna M, et al. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolemia- A post-hoc analysis of a phase 3, single-arm, open-label trial. Atherosclerosis. 2015;240:408–414. doi:10.1016/j.atherosclerosis.2015.03.014
   PubMed Web of Science ®Google Scholar
• Blom D, Averna M, Meagher E, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor Lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136:332–335. doi:10.1161/CIRCULATIONAHA.117.028208
   PubMed Web of Science ®Google Scholar
• Nohara A, Otsubo Y, Yanagi K, et al. Safety and efficacy of lomitapide in japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGR-733-301 Long-term extension trial. J Atheroscler Thromb. 2018. doi:10.5551/jat.45708
   Web of Science ®Google Scholar
• Blom D, Fayad Z, Kastelein J, et al.; on behalf of the Lower investigators. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and desing. J Clin Lipidol. 10;2016:273–282. doi:10.1016/j.jacl.2015.11.011
   PubMed Web of Science ®Google Scholar
• Underberg J, Cannon C, Larrey D, Makris L, Jurecka A, Blom D Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: three year data from the lomitapide observational worldwide evaluation registry (LOWER). Presented at the American College of Cardiology in Orlando; March 10–12, 2018; Florida. doi:10.1016/S0735-1097(18)30709-5
   Google Scholar
• D’Erasmo L, Cefalù AB, Noto D, et al. Efficacy of Lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world experience in Italy. Adv Ther. 2017;34:1200–1210. doi:10.1007/s12325-017-0531-x
   PubMed Web of Science ®Google Scholar
• Alonso R, Mata P, Alonso YGM, de Andres R. Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B. Med Clin (Barc). 2015;145(5):229–230. doi:10.1016/j.medcli.2014.11.002
   PubMed Web of Science ®Google Scholar
• Raper A, Kolansky D, Sachais B, Meagher E, Baer A, Cuchel M. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. J Clin Lipidol. 2015;9:107–112. doi:10.1016/j.jacl.2014.08.005
   PubMed Web of Science ®Google Scholar
• Kolovou G, Kolovou V, Papadopoulou A, Watts G. MTP gene variants and response to lomitapide in patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2016;23:878–883. doi:10.5551/jat.34777
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: experienceswith lomitapide. J Clin Lipidol. 2015;9:607–617. doi:10.1016/j.jacl.2015.05.001
   PubMed Web of Science ®Google Scholar
• Real J, Arbona C, Goterris R, Ascaso JF. Management of homozygous familial hypercholesterolemia in two brothers. BMC Case Rep. 2018;2018. Pii: bcr-2017-222155. doi:10.1136/bcr-2017-222155
   Google Scholar
• Thompson G, Blom D, Marais AD, Seed M, Pilcher G, Raal F. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018;39:1162–1168. doi:10.1093/eurheartj/ehx317
   PubMed Web of Science ®Google Scholar
• Chacra APM, Ferrari MC, Rocha VZ, Santos RD. Case report: the efficiency and safety of lomitapide in a homozygous familial hypercholesterolemic child. J Clin Lipidol. 2019;11. Pii: S1933-S2874(19)30043-1. doi:10.1016/j.jacl.2019.03.001
   Web of Science ®Google Scholar
• Leipold R, Raal F, Ishak J, Hovingh K, Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis. Eur J Prev Cardiol. 2017;24:1843–1850. doi:10.1177/2047487317730473
   PubMed Web of Science ®Google Scholar
• Blom D, Cuchel M, Ager M, Phillips H. Target achievement and cardiovascular event rates with lomitapide in homozygous familial hypercholesterolemia. Orphanet J Rare Dis. 2018;13(1):96. doi:10.1186/s13023-018-0841-3
   PubMedGoogle Scholar
• Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJP. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial Hypercholesterolemia. J Clin Lipidol. 2016;10:1011–1021. doi:10.1016/j.jacl.2016.04.013
   PubMed Web of Science ®Google Scholar
• Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolemia: an interin subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5:280–290. doi:10.1016/S2213-8587(17)30044-X
   PubMed Web of Science ®Google Scholar
• Liu X, Men P, Wang Y, Zhai A, Zhao A. Efficacy and safety of lomitapide in hypercholesterolemia. Am J Cardiovasc Drugs. 2011;17:299–309. doi:10.1007/s40256-017-0214-7
   Google Scholar
• Sacks F, Stanesa M, Hegele R. Severe hypertriglyceridemia with pancreatitis. Thirteen years´treatment with lomitapide. JAMA Intern Med. 2014;174:443–447. doi:10.1001/jamainternmed.2013.13309
   PubMed Web of Science ®Google Scholar